[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Mirum Pharmaceuticals Inc (MIRM)

Mirum Pharmaceuticals Inc (MIRM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,534,756
  • Shares Outstanding, K 64,932
  • Annual Sales, $ 521,310 K
  • Annual Income, $ -23,360 K
  • EBIT $ -834 M
  • EBITDA $ -808 M
  • 60-Month Beta 0.52
  • Price/Sales 12.30
  • Price/Cash Flow 1,937.46
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 34.82% (-1.24%)
  • Historical Volatility 53.55%
  • IV Percentile 2%
  • IV Rank 4.35%
  • IV High 99.96% on 04/10/26
  • IV Low 31.86% on 08/21/25
  • Expected Move (DTE 6) 0.85 (0.84%)
  • Put/Call Vol Ratio 3.00
  • Today's Volume 8
  • Volume Avg (30-Day) 112
  • Put/Call OI Ratio 0.58
  • Today's Open Interest 3,740
  • Open Int (30-Day) 2,557
  • Expected Range 99.79 to 101.49

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.61
  • Number of Estimates 5
  • High Estimate $-0.31
  • Low Estimate $-0.87
  • Prior Year $0.05
  • Growth Rate Est. (year over year) -1,320.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
88.88 +13.23%
on 08/06/26
121.49 -17.16%
on 07/15/26
-20.25 (-16.75%)
since 07/14/26
3-Month
88.88 +13.23%
on 08/06/26
130.00 -22.58%
on 07/09/26
-10.75 (-9.65%)
since 05/14/26
52-Week
63.23 +59.16%
on 12/15/25
130.00 -22.58%
on 07/09/26
+35.81 (+55.24%)
since 08/14/25

Most Recent Stories

More News
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that on August 10, 2026, the Compensation Committee of Mirum’s Board of Directors granted inducement awards...

MIRM : 100.64 (+1.89%)
Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

- Q2 2026 net product sales of $176 million - 2026 net product sales guidance increased to $680 million to $700 million - Volixibat...

MIRM : 100.64 (+1.89%)
Mirum's Rare Disease Bet Faces Its Most Important Proof Point

Barchart Research What to Expect from MIRM Earnings MIRM Generated August 4, 2026 Current Price $104.33 EPS Estimate $$-0.77 Consensus Rating Strong Buy Average Move 7.24% Mirum's Rare Disease Bet Faces...

MIRM : 100.64 (+1.89%)
Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will report second quarter 2026 financial results on August 5, 2026. Mirum will also host a conference...

MIRM : 100.64 (+1.89%)
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that on July 10, 2026, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting...

MIRM : 100.64 (+1.89%)
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva

- Cohort 1 results presented at ENDO 2026 demonstrate meaningful reductions in total heterotopic ossification (HO) lesion volume, new HO lesions and flare activity in adolescents and adults with...

MIRM : 100.64 (+1.89%)
INCY : 120.16 (-0.30%)
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that on June 10, 2026, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting...

MIRM : 100.64 (+1.89%)
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026

- Late-breaking rapid-fire presentation to include results from Cohort 1 of the placebo-controlled PROGRESS study evaluating zilurgisertib in fibrodysplasia ossificans progressiva (FOP)

MIRM : 100.64 (+1.89%)
INCY : 120.16 (-0.30%)
Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026

- Late-breaking VISTAS results demonstrate rapid, sustained, and clinically meaningful reductions in pruritus with volixibat in primary sclerosing cholangitis (PSC) -...

MIRM : 100.64 (+1.89%)
Mirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline Advance

Mirum Pharmaceuticals (NASDAQ:MIRM) executives said the rare disease company is entering a catalyst-heavy period, with recent positive clinical updates, ongoing commercial momentum for LIVMARLI and additional...

MIRM : 100.64 (+1.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's product candidate consists of maralixibat, an investigational oral drug in development...

See More

Key Turning Points

3rd Resistance Point 106.97
2nd Resistance Point 104.14
1st Resistance Point 102.39
Last Price 100.64
1st Support Level 97.81
2nd Support Level 94.98
3rd Support Level 93.23

See More

52-Week High 130.00
Fibonacci 61.8% 104.49
Last Price 100.64
Fibonacci 50% 96.62
Fibonacci 38.2% 88.74
52-Week Low 63.23

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.